2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4602 Localizing the socioeconomic survival gap in AML: Disparities drive access to specialized care and transplant, not post-transplant survival

Parisa Abedi, MD, Luca Lanino, MD2, Rohan K Achar, MD, MSCR3, Henry Dumke, MD4, Razan Mansour, MD5, Nurefsan Sariipek, MD6, Benjamin Rolles, MD7, Abdulrahman Alhajahjeh, MD8, Jan Philipp Bewersdorf, MD9, Luis E. Aguirre, MD, MPH10, Nikolai Podoltsev, MD, PhD11, Lourdes Mendez, MD12, Lohith Gowda, MD13, Stuart Seropian, MD14, Alain Mina, MD15, Amer M. Zeidan, MD16, Maximilian Stahl, MD17
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 Yale School of Medicine, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States
7 Yale School of Medicine, New Haven, Connecticut, United States
8 Yale School of Medicine, New Haven, Connecticut, United States
9 Yale School of Medicine, New Haven, Connecticut, United States
10 Yale School of Medicine, New Haven, Connecticut, United States
11 Yale School of Medicine, New Haven, Connecticut, United States
12 Yale School of Medicine, New Haven, Connecticut, United States
13 Yale School of Medicine, New Haven, Connecticut, United States
14 Yale School of Medicine, New Haven, Connecticut, United States
15 Yale School of Medicine, New Haven, Connecticut, United States
16 Yale School of Medicine, New Haven, Connecticut, United States
17 Yale School of Medicine, New Haven, Connecticut, United States

Introduction: Although socioeconomic disparities in cancer survival are well described, the care-delivery mechanisms that account for socioeconomic status (SES)-associated mortality in acute myeloid leukemia (AML) remain incompletely characterized. Hence, we sought to quantify the independent prognostic effect of area-level SES in patients (pts) with newly diagnosed AML treated with intensive chemotherapy (IC) or venetoclax plus hypomethylating agent (HV), localize disparities to specific care transitions, and benchmark the SES effect against established molecular risk classifications.

Methods: Adults with newly diagnosed AML in the Flatiron Health Research Database (2014–2024) receiving first-line intensive chemotherapy (IC; n=3,927) or venetoclax plus hypomethylating agents (HV; n=2,051) were evaluated. Area-level SES was assigned via the ACS-derived Yost Index (census block group; Q1 = lowest SES) and modeled as binary Low (Q1–Q2) vs High (Q3–Q5; reference), 5-level categorical, and a linear trend across quintiles. Multivariable Cox models adjusted for age, sex, ECOG performance status, ethnicity (race), and disease-risk biology (ELN 2022 for IC; PRISM for HV). Using an identical covariate set, an illness-death multistate model stratified the SES effect on overall survival across three key care transitions: T1 (Diagnosis to HSCT; reflecting access to HSCT), T2 (Diagnosis to Death; reflecting pre/non-transplant mortality), and T3 (HSCT to Death; reflecting post-transplant mortality).

Results:  Among 5,978 adults, low- vs high-SES was independently associated with 21-28% increase in mortality across both cohorts (IC: adjusted HR [aHR] 1.21, 95% CI 1.05-1.40, p=0.007; HV: aHR 1.28, 95% CI 1.08-1.52, p=0.004).

Supporting a dose-response relationship, each single-quintile decrease in SES independently increased mortality hazard by 5% across both cohorts (IC: aHR 1.05, 95% CI 1.02–1.08, p<0.001; HV: aHR 1.05, 95% CI 1.01–1.09, p=0.014). Benchmarking against molecular risk revealed that the Q1-vs-Q5 hazard disadvantage equaled one-third to one-half of a single biological risk-tier step. Specifically, the SES hazard gap represented 36% of the risk shift from ELN 2022 Favorable to Intermediate risk in IC-treated pts (aHR 1.69, 95% CI 1.50–1.89) and 48% of the shift from PRISM Low to Moderate risk in HV-treated pts (aHR 1.67, 95% CI 1.49–1.87).

This survival gap reflected structural disparities in access to specialized care. Among IC-treated pts, low SES (Q1 vs Q5) independently reduced the odds of receiving care at an academic center (aOR 0.33, 95% CI 0.26–0.42, p<0.001), HSCT receipt (aOR 0.38, 95% CI 0.30–0.48, p<0.001), and enrollment in a clinical trial (aOR 0.31, 95% CI 0.16–0.57, p<0.001). These structural barriers were further amplified in HV-treated pts for both academic care (aOR 0.20, 95% CI 0.13–0.30, p<0.001) and HSCT receipt (aOR 0.27, 95% CI 0.13–0.51, p<0.001).

Multistate modeling localized where along the care trajectory this mortality gap arises. IC-treated pts with low (vs high) SES experienced reduced access to HSCT (T1 aHR 0.58, p<0.001) and higher pre/non-transplant mortality (T2 aHR 1.14, p=0.012), but no difference in post-transplant survival (T3 aHR 1.00, p=0.97). In HV-treated pts, low SES was associated with reduced HSCT access (T1 aHR 0.65, p=0.019), without significant differences in pre/non-transplant (T2 aHR 1.08, p=0.17) or post-transplant mortality (T3 aHR 1.31, p=0.27; imprecise estimate due to few transplanted HV pts). Together, these findings indicate that while reduced transplant access drives disparities in both cohorts, excess pre/non-transplant mortality additionally compounds this gap in IC-treated pts but not in HV-treated pts, with no post-transplant survival differences in either group.

Conclusions: Lower SES independently increases adjusted AML mortality by 5% per quintile decrease. Reduced access to HSCT drives outcome disparities between low- and high-SES patients treated with either IC or HV. In addition, excess pre-/non-transplant mortality among low-SES patients further contributes to this survival gap in IC-treated, but not HMA/VEN-treated, patients. For those who undergo HSCT, post-transplant survival shows no SES disparity.

Parisa Abedi, MD: No relevant conflicts of interest to declare.